Many large pharmaceutical companies in the U.S. pay very low taxes, with effective tax rates far below the 21% corporate tax rate. Pfizer, for example, reported a negative effective tax rate despite booking $59 billion in revenue.
Key Points
Pharmaceutical companies report losing money in the U.S. despite high sales due to complex tax strategies
Pfizer reported a negative effective tax rate for 2023 despite significant revenue
Tax laws and loopholes allow companies to minimize tax payments
Pros
Companies legally minimizing taxes
Cons
Potential loss of tax revenue for the U.S. government